{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:05:00Z","timestamp":1772751900287,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:00:00Z","timestamp":1489708800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00063-017-0271-3","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T06:16:40Z","timestamp":1489731400000},"page":"206-213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Neue Antibiotika \u2013 Stillstand oder Fortschritt","New antibiotics \u2013 standstill or progress"],"prefix":"10.1007","volume":"112","author":[{"given":"J.","family":"Rademacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Welte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,17]]},"reference":[{"issue":"1","key":"271_CR1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","volume":"59","author":"SS Awad","year":"2014","unstructured":"Awad SS, Rodriguez AH, Chuang YC, Marjanek Z, Pareigis AJ, Reis G, Scheeren TW, S\u00e1nchez AS, Zhou X, Saulay M, Engelhardt M (2014) A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 59(1):51\u201361","journal-title":"Clin Infect Dis"},{"issue":"2","key":"271_CR2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(14)71018-7","volume":"15","author":"NS Zhong","year":"2015","unstructured":"Zhong NS, Sun T, Zhuo C et al (2015) Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a\u00a0randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis 15(2):161\u2013171","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"271_CR3","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1128\/AAC.00197-13","volume":"57","author":"D Oldach","year":"2013","unstructured":"Oldach D, Clark K, Schranz J et al (2013) Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother 57(6):2526\u20132534","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"271_CR4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","volume":"54","author":"RG Wunderink","year":"2012","unstructured":"Wunderink RG, Niederman MS, Kollef MH et al (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a\u00a0randomized, controlled study. Clin Infect Dis 54(5):621\u2013629","journal-title":"Clin Infect Dis"},{"issue":"1","key":"271_CR5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.22620","volume":"49","author":"AD Brinker","year":"2009","unstructured":"Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM, Seeff LB (2009) Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 49(1):250\u2013257","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"271_CR6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12450","volume":"20","author":"J Chastre","year":"2014","unstructured":"Chastre J, Blasi F, Masterton RG et al (2014) European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect 20(Suppl 4):19\u201336","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"271_CR7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","volume":"309","author":"P Prokocimer","year":"2013","unstructured":"Prokocimer P, De Anda C, Fang E et al (2013) Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 309(6):559\u2013569","journal-title":"JAMA"},{"issue":"8","key":"271_CR8","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","volume":"14","author":"GJ Moran","year":"2014","unstructured":"Moran GJ, Fang E, Corey GR et al (2014) Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a\u00a0randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 14(8):696\u2013705","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"271_CR9","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/jac\/dku035","volume":"69","author":"P Gastmeier","year":"2014","unstructured":"Gastmeier P, Schr\u00f6der C et al (2014) Dramatic increase in vancomycin-resistant enterococci in Germany. J\u00a0Antimicrob Chemother 69(6):1660\u20131664","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"271_CR10","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","volume":"60","author":"J Solomkin","year":"2015","unstructured":"Solomkin J, Hershberger E, Miller B et al (2015) Ceftolozane\/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a\u00a0Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis 60(10):1462\u20131471","journal-title":"Clin Infect Dis"},{"issue":"9981","key":"271_CR11","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner FM, Umeh O, Steenbergen J et al (2015) Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a\u00a0randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385(9981):1949\u20131956","journal-title":"Lancet"},{"issue":"5","key":"271_CR12","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","volume":"68","author":"C Lucasti","year":"2013","unstructured":"Lucasti C, Popescu I, Ramesh MK et al (2013) Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a\u00a0randomized, double-blind, phase II trial. J\u00a0Antimicrob Chemother 68(5):1183\u20131192","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"271_CR13","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","volume":"62","author":"JE Mazuski","year":"2016","unstructured":"Mazuski JE, Gasink LB, Armstrong J et al (2016) Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a\u00a0randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 62(11):1380\u20131389","journal-title":"Clin Infect Dis"},{"issue":"12","key":"271_CR14","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","volume":"28","author":"JA Vazquez","year":"2012","unstructured":"Vazquez JA, Gonz\u00e1lez Patz\u00e1n LD et al (2012) Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a\u00a0prospective, investigator-blinded, randomized study. Curr Med Res Opin 28(12):1921\u20131931","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"271_CR15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB (2016) Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a\u00a0randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16(6):661\u2013673","journal-title":"Lancet Infect Dis"},{"key":"271_CR16","volume-title":"Annual epidemiological report 2014. Antimicrobial resistance and healthcare-associated infections","author":"European Centre for Disease Prevention and Control","year":"2015","unstructured":"European Centre for Disease Prevention and Control (2015) Annual epidemiological report 2014. Antimicrobial resistance and healthcare-associated infections. ECDC, Stockholm ( http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/antimicrobial-resistance-annual-epidemiological-report.pdf )"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-017-0271-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00063-017-0271-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-017-0271-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T21:39:05Z","timestamp":1568929145000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00063-017-0271-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,17]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["271"],"URL":"https:\/\/doi.org\/10.1007\/s00063-017-0271-3","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"value":"2193-6218","type":"print"},{"value":"2193-6226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,17]]}}}